APA (7th ed.) Citation

Siena, S., Douillard, J., Cassidy, J., Tabernero, J., Burkes, R., Barugel, M., . . . Krishnan, K. (2011). 6143 POSTER Study 20050203/PRIME – Effect of Post-Progression Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody (mAb) Therapy in Patients With Wild-Type (WT) KRas Metastatic Colorectal Cancer (mCRC). European Journal of Cancer, 47, S435. https://doi.org/10.1016/S0959-8049(11)71788-9

Chicago Style (17th ed.) Citation

Siena, S., et al. "6143 POSTER Study 20050203/PRIME – Effect of Post-Progression Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody (mAb) Therapy in Patients With Wild-Type (WT) KRas Metastatic Colorectal Cancer (mCRC)." European Journal of Cancer 47 (2011): S435. https://doi.org/10.1016/S0959-8049(11)71788-9.

MLA (9th ed.) Citation

Siena, S., et al. "6143 POSTER Study 20050203/PRIME – Effect of Post-Progression Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody (mAb) Therapy in Patients With Wild-Type (WT) KRas Metastatic Colorectal Cancer (mCRC)." European Journal of Cancer, vol. 47, 2011, p. S435, https://doi.org/10.1016/S0959-8049(11)71788-9.